CN101862413A - Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof - Google Patents
Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN101862413A CN101862413A CN 201010221561 CN201010221561A CN101862413A CN 101862413 A CN101862413 A CN 101862413A CN 201010221561 CN201010221561 CN 201010221561 CN 201010221561 A CN201010221561 A CN 201010221561A CN 101862413 A CN101862413 A CN 101862413A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- preparation
- weight
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 23
- 241000208340 Araliaceae Species 0.000 claims abstract description 47
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 46
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 46
- 235000008434 ginseng Nutrition 0.000 claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 27
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 239000000706 filtrate Substances 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 71
- 241000545442 Radix Species 0.000 claims description 20
- 238000005303 weighing Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 3
- 235000019640 taste Nutrition 0.000 claims description 3
- 241000143437 Aciculosporium take Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 36
- 239000008280 blood Substances 0.000 abstract description 36
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 18
- 239000008103 glucose Substances 0.000 abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 235000006533 astragalus Nutrition 0.000 abstract description 6
- 241001061264 Astragalus Species 0.000 abstract description 4
- 210000004233 talus Anatomy 0.000 abstract description 4
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 235000012054 meals Nutrition 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 3
- 244000182216 Mimusops elengi Species 0.000 abstract 3
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 3
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 3
- 241000405414 Rehmannia Species 0.000 abstract 3
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 3
- 235000021028 berry Nutrition 0.000 abstract 3
- 238000001914 filtration Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 23
- 239000009636 Huang Qi Substances 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 230000002218 hypoglycaemic effect Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000008187 granular material Substances 0.000 description 11
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 10
- 235000021286 stilbenes Nutrition 0.000 description 10
- 230000035922 thirst Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 4
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 210000004923 pancreatic tissue Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 2
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108010047909 Resistin Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000001654 beetroot red Substances 0.000 description 2
- 235000012677 beetroot red Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000002185 betanin Nutrition 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000008517 radix Trichosanthis Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000009874 shenqi Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- -1 steroidal class Substances 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 241000252335 Acipenser Species 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- VDWSYBFEQXWINA-UHFFFAOYSA-N Martinoside Natural products C1=C(O)C(OC)=CC=C1CCOC1C(O)C(OC2C(C(O)C(O)C(C)O2)O)C(OC(=O)C=CC=2C=C(O)C(OC)=CC=2)C(CO)O1 VDWSYBFEQXWINA-UHFFFAOYSA-N 0.000 description 1
- 241001608711 Melo Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 241000209051 Saccharum Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- WLWAYPFRKDSFCL-CNMJWYMJSA-N [(2r,3r,4r,5r,6r)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(OC)=CC=C1CCO[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)[C@@H](CO)O1 WLWAYPFRKDSFCL-CNMJWYMJSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- RLGRBYHBNWLGER-UHFFFAOYSA-N cistanoside D Natural products C1=C(O)C(OC)=CC(CCOC2C(C(OC3C(C(O)C(O)C(C)O3)O)C(OC(=O)C=CC=3C=C(OC)C(O)=CC=3)C(CO)O2)O)=C1 RLGRBYHBNWLGER-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- ZMYQRHSOVRDQDL-NSWBACJASA-N leucosceptoside A Natural products COc1cc(C=CC(=O)O[C@@H]2[C@@H](CO)O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@H]2O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)ccc1O ZMYQRHSOVRDQDL-NSWBACJASA-N 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WLWAYPFRKDSFCL-AYPSUWEUSA-N martynoside Natural products COc1ccc(CCO[C@@H]2O[C@H](CO)[C@@H](OC(=O)C=Cc3ccc(O)c(OC)c3)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@H]2O)cc1O WLWAYPFRKDSFCL-AYPSUWEUSA-N 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 108700040801 rat Retn Proteins 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal preparation for treating the type-2 diabetes and a preparation method thereof. The preparation is prepared from the following bulk pharmaceutical chemicals in part by weight: 5 to 60 parts of astragalus, 3 to 20 parts of ginseng, 5 to 20 of cooked rehmannia root, 5 to 20 parts of dwarf lilyturf tuber, 5 to 30 parts of medlar, and 1 to 10 parts of shizandra berry. The preparation method comprises the following steps of: mixing the astragalus, the cooked rehmannia root, the dwarf lilyturf tuber, the medlar and the shizandra berry in weight part ratio, adding water into a mixture and decocting the mixture for two times, wherein the water is added in an amount which is 8 times total weight parts of the astragalus, the cooked rehmannia root, the dwarf lilyturf tuber, the medlar and the shizandra berry; and the decoction time is two hours each time; filtering the decocted mixture, and merging the filtrate and concentrating the filtrate to form extractum; and drying the ginseng, smashing the ginseng to 200-mesh fine powder, mixing the ginseng fine powder and the extractum, drying the mixture, and smashing the mixture into the fine powder which serves as an active ingredient and is prepared into various formulations together with a pharmaceutically acceptable carrier or excipient. The Chinese medicinal preparation has the advantages of scientific and reasonable formula, capability of reducing fasting blood-glucose and blood glucose in 2 hours after a meal of a type-2 diabetic patient, long effective time, the effects of reducing blood glucose, regulating lipid and reducing blood viscosity, and obvious effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine for the treatment of type 2 diabetes mellitus and preparation method thereof.
Background technology
Type 2 diabetes mellitus also is adult's morbidity type diabetes, how falls ill after 35-40 year, accounts for diabetics more than 90%.It is a kind of common endocrine metabolism obstacle disease, the ability that produces insulin in the type 2 diabetes mellitus patient body is not to completely lose, insulin even produce too much in the patient's body that has, but the action effect of insulin has a greatly reduced quality, so the intravital insulin of patient is a kind of relative shortage.Though can stimulate secretion of insulin in the body by some oral drugs.But still have the part patient need as type 1 diabetes, carry out insulinize to the later stage.Its sickness rate has the trend that increases in the China and even the world, has become the third-largest disease after cardiovascular disease, tumor.The medicine for the treatment of diabetes in the market is various, and by retrieval, Chinese patent and Chinese periodical disclose the report of the relevant Chinese medicine preparation of following treatment diabetes, now take passages as follows:
1, Chinese patent＜application number〉00108421＜denomination of invention〉a kind of medicine for the treatment of diabetes and preparation method thereof＜applicant〉Korea Spro ten thousand bright Liu Ping, First People's Hospital, the Yangquan City Li Jia village, Shanxi Province branch＜digest〉the invention discloses a kind of medicine of new treatment diabetes, it is with Radix Astragali, the Radix Rehmanniae, Radix Salviae Miltiorrhizae, Rhizoma Dioscoreae, Semen Litchi, Radix Scrophulariae, Rhizoma Atractylodis, Fructus Lycii, Fructus Mume, Stigma Maydis, Fructus Schisandrae Chinensis, Radix Trichosanthis, Pedicellus Melo, Cortex Cinnamomi, Pupa bombycis, Ramulus Euonymi, Concha Meretricis seu Cyclinae, Endothelium Corneum Gigeriae Galli, Radix Puerariae, Folium Mori, Rhizoma Polygonati is a raw material, different different qualities according to every flavor Chinese medicine passes through lyophilizing respectively, dry, calcining, dedusting, pulverize, preparation in proportion, through ripening, make powder after the sterilization again.The present invention is on the secret recipe of having collected up to a hundred treatment diabetes among the people, studies intensively with great concentration according to several generations again, and the clinical treatment experience gained, prescription is unique, and therapeutic effect is remarkable.
2, Chinese patent＜application number〉99120424＜denomination of invention〉a kind of medicine for the treatment of diabetes and preparation method thereof＜applicant〉Shao Yujun＜digest〉the invention discloses a kind of Chinese patent medicine for the treatment of diabetes and preparation method thereof, this Chinese patent medicine is with Pollen Pini, Endothelium Corneum Gigeriae Galli, the Radix Astragali, Radix Pseudostellariae, Cortex Phellodendri, Stigma Maydis, the Rhizoma Anemarrhenae, Radix Rehmanniae, Rhizoma Polygonati, Cortex Mori, Rhizoma Dioscoreae, Semen Litchi, Radix Salviae Miltiorrhizae, Fructus Corni, spice in Radix Et Rhizoma Rhei and Fructus Schisandrae Chinensis 16 flavors, be divided into four groups according to its effective ingredient and physicochemical property, adopt decocting respectively, water decoction-alcohol sedimentation, the technology of directly being used as medicine after ethanol extraction and the pulverizing, be prepared into capsule, the treatment diabetes, curative effect was both remarkable, and was without any side effects again.
3, treating the Chinese patent medicine that diabetes (diabetes) Chinese patent medicine commonly used is made up of seven flavor Chinese medicines at present has: (1) hypoglycemic granule (Radix Astragali, Radix Ophiopogonis, the Radix Rehmanniae, Rhizoma Polygonati, Radix Achyranthis Bidentatae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae); (2) blood-sugar reducing tablets (Rhizoma Dioscoreae, Radix Ginseng Rubra, Radix Trichosanthis, Rhizoma Polygonati, Fructus Mori, Saccharum sinensis Roxb, Folium Stevlae Rebaudianae); (3) Rhizoma Polygonati Rhizoma Dioscoreae capsule (Fructus Lycii, Rhizoma Polygonati Odorati, Rhizoma Dioscoreae, Rhizoma Polygonati, Radix Puerariae, the West flower, Air Bladder pseudosciaenae seu Acipenser); (4) brave nation's Jiangtang capsule (Testis Et penis Caprae seu Ovis, Testis Et penis Bovis seu Bubali, Fructus Mori, Rhizoma Dioscoreae, Rhizoma Polygonati, Fructus Lycii, Lac regis apis lyophilized powder); (5) Fructus Lycii diabetes capsule (bright Fructus Hippophae, fresh fructus lycii, Cortex Lycii, Fructus Crataegi, Rhizoma Dioscoreae, the Radix Astragali, Fructus Hordei Germinatus).
4, the Radix Astragali is to clinical research [author] Zhou Li of diabetes insulin opposing and Serum adiponectin influence, Zhang Shuhui, in treasure, Zou Kaili [mechanism] Changsha the 4th Nuclear Medicine Department of hospital, [periodical name] new traditional Chinese medical science .2007,39 (5): 82～83.[digest] purpose: observe the influence of the Radix Astragali to diabetes insulin opposing and serum fat contact level.The result: serum fat contact level compares for 2 groups before the treatment, and difference does not have significance meaning (p＞0.05).After the treatment, Radix Astragali group fasting glucose, glycolated hemoglobin reduce, and insulin resistant obviously improves, and serum fat contact level significantly raises, and treat the back relatively with reaching placebo group before the treatment, and difference all has significance meaning (p＜0.05).
5, the Radix Astragali is to research [author] Chen Zhihong of insulin β cytoprotection; Li Tang; the journal .2009 of Beijing University of Chinese Medicine of Sun Xiufang [mechanism] Hospital Attached to Medical College, Qingdao Univ. [periodical name]; 32 (3): 182～184.[digest] purpose: inquire into the influence that streptozotocin (STZ) produces nitric oxide (NO) and insulin to rat Langerhans islet β cell, and the Radix Astragali is to the protective effect of beta Cell of islet.The result: 10% and 20% Radix Astragali injection pretreated group all can significantly reduce NO level in the cell culture fluid, and protection β cell insulin secretion suppresses apoptosis and the propagation that promotes cell.
6, Radix Ginseng and main component antidiabetic effect mechanism [author] Shang Wenbin thereof, Yang Ying, Chen Mingdao [mechanism] Shanghai Endocrine-Metabolic Diseases Inst., [periodical name] international endocrine metabolism magazine .2007,27 (2): 115～117.[digest] clinical and experimentation shows that Radix Ginseng and active component thereof have the adjusting glycolipid metabolism, anti-diabetic and fat effect.Its mechanism of action is main and suppress intestinal glucose and fatty absorption, influences the glycolipid metabolism path, increases energy expenditure; Regulate the active and expression of peroxisome proliferation activated receptor R (PPARR), improve insulin resistant, the promotion insulin synthesizes and discharges, and anti-beta Cell of islet apoptosis; Anti-oxidation stress is relevant with antiinflammatory action.
7, the antidiabetic effect progress of Radix Ginseng, Radix Panacis Quinquefolii and main active thereof summary [author] Zhang Li, Li Xia [mechanism] Lanzhou Military Region Urumqi General Hospital Pharmacy department, [periodical name] pharmaceutical services and research .2009,9 (2): 122～125.[digest] this paper has summarized Radix Ginseng, Radix Panacis Quinquefolii and main active blood sugar control thereof, has improved the relevant metabolism disorder of diabetes and the progress of related mechanism thereof with reference to domestic and foreign literature.
8, the yellow fluid extract is to influence [author] Lv Xiufang of type 2 diabetes mellitus rat insulin opposing R resistin gene mRNA and protein expression, Meng Qingyu, Biochemistry and Molecular Biology teaching and research room of Guo new people [mechanism] Mudanjiang Medical College, [periodical name] CHINA JOURNAL OF CHINESE MATERIA MEDICA .2007,32 (20): 2182～2184.[digest] purpose: inquire into of the influence of Chinese medicine ground yellow fluid extract to type 2 diabetes mellitus rat glycolipid metabolism and resistin gene expression.The result: Radix Rehmanniae treatment group rat significantly reduces (p＜0.05) than model group rat resistin gene mRNA and protein expression.Each treatment group FPG, FINS, TG, LDL, content and the IR of CH significantly reduces (p＜0.05), and HDL is significantly rising (p＜0.05) then.
9, the yellow fluid extract is to the influence of type 2 diabetes mellitus P of Rats roinsulin gene expression.[author] Meng Qingyu, Lv Xiufang, Jin Xiudong [mechanism] Mudanjiang Medical College, [periodical name] Chinese crude drug .2008,31 (3): 397～399.[digest] purpose: the molecules mechanism of inquiring into ground yellow fluid extract treatment type 2 diabetes mellitus (2-DM).The result compares with the 2-DM model, and Radix Rehmanniae treatment group P of Rats roinsalin gene mRNA and protein expression significantly increase (p＜0.01), and FPG significantly reduces, and FINS, IS, HBCI raise, and difference all has significance.
10, the experimentation of Radix Rehmanniae catalpol blood sugar reducing function [author] Zhao Surong, Lu's Yan is big, Chen Jinlong, Duan Haifeng, Wu Zuze [mechanism] is Bengbu Medical College 1., 2. radiation of Chinese People's Liberation Army's thing medical courses in general institute and radiation medicine institute, precious traditional Chinese medical science traditional Chinese medicines .2009 when [periodical name], 32 (1): 171～172.[digest] purpose: research Radix Rehmanniae catalpol causes the influence of blood glucose in diabetic mice to alloxan.The result: catalpol can obviously reduce the blood sugar level that alloxan causes diabetic mice, improves carbohydrate tolerance and blood lipid level, and is dose-dependence.
11, Radix Ophiopogonis total saponins is to blood sugar reducing function [author] Gao Changkun of experimental hyperglycemia mice, height is built, Xu Xianxiang [mechanism] is Pharmacy department of The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine 1., [periodical name] Chinese experimental pharmacology of Chinese medical formulae magazine .2007,13 (5): 33～34.[digest] purpose: the research Radix Ophiopogonis total saponins is to the influence of tissue of experimental diabetic mice blood glucose.The result: Radix Ophiopogonis total saponins all has inhibitory action to the mice hyperglycemia that alloxan, epinephrine and glucose cause.
12, the pharmacodynamic observation of Radix Ophiopogonis polysaccharide hypoglycemic activity.The land-reclaimable central hospital in Guangdong, [author] He Ling Hunan [mechanism], Zhanjiang, [periodical name] practical medical .2007 of China, 2 (16): 48～50.[digest] purpose: observe the influence of Radix Ophiopogonis polysaccharide, for clinical trial provides experimental basis to blood glucose.The result: Radix Ophiopogonis polysaccharide (75,150,300mg/kg) does not have obvious influence to normal mouse blood sugar; But can reduce blood glucose and glycolated hemoglobin that streptozotocin brings out hyperglycemic rat, blood sugar increasing time and blood sugar lowering concentration after the oral sucrose of deferrable rat.
13, single medicinal material Fructus Lycii hypoglycemic activity reaches experimentation [author] Tian Limei to pancreatic tissue morphology influence; king's Min [mechanism] China Medicine University's life and technical college, the Nanjing, [periodical name] Chinese medicine circular .2005,4 (1): 48～51.[digest] purpose: research Chinese medicine Fructus Lycii is to the hypoglycemic activity of diabetic mice and to the morphologic influence of pancreatic tissue.The result: the Chinese medicine Fructus Lycii can obviously reduce the blood glucose (p＜0.01) of diabetic mice, serum insulin levels is had the trend of raising.The pancreatic tissue morphological examination finds that the B cell number obviously reduces the nucleus skewness in islets of langerhans district, the regional hypochromatosis that has before the treatment.After the treatment, each organizes the beta Cell of islet number increases, and damaged cell recovers.
14, the pharmacodynamic study of Fructus Lycii hypoglycemic activity [author] Tan Shumin [mechanism] Guangdong People's Hospital, Guangzhou, Guangdong [periodical name] the journal .2008 of Nanjing Medical University, 28 (11): 2103～2104.[digest] purpose: the hypoglycemic activity of inquiring into the Chinese medicine Fructus Lycii.The result: 3 dosage groups of Fructus Lycii all have inhibitory action to the hyperglycemia of glucose, epinephrine, 3 kinds of hyperglycemia model mices of alloxan, and normal mouse and spontaneous hyperglycemia mice are also had obvious hypoglycemic activity.
15, in the Fructus Schisandrae Chinensis-glucosidase inhibitor is to hypoglycemic activity [author] Yuan Haibo of mice, Shen Zhongming, Yin Jianwei, life sciences institute of Xu Linfeng [mechanism] Shanghai University, [periodical name] Chinese biochemical drug magazine .2002,23 (3): 112～114.[digest] purpose: inquire into Fructus Schisandrae Chinensis contained-activity in vivo of glucosidase inhibitor.The result: from the Chinese medicine Fructus Schisandrae Chinensis, separate obtain-glucosidase inhibitor may have good blood sugar reducing function.
Though the medicine of many treatment diabetes is arranged at present and such as the report of above-mentioned development diabetes, and obtained certain curative effect, but clinical cure rate is still undesirable, especially to type 2 diabetes mellitus bounce-back property at a specified future date height, effectively blood sugar control, blood fat, blood viscosity cause frequent recurrence.And the Chinese medicine medicine cost that has is too high, and it is numerous and diverse that medicine is formed, and composition is wayward, and side effect is bigger, therefore research and develop a kind of therapeutic effect better, do not have the medicine of the little type 2 diabetes mellitus of toxic and side effects ready to appear.
Summary of the invention
The objective of the invention is at prior art bounce-back property height, medicine is formed numerous and diverse, cost is too high, composition is wayward, many deficiencies that side effect is bigger, one provide that a kind of medicament composing prescription is reasonable, safe in utilization, evident in efficacy, side effect is little, moderate, easy to make, the medicine source abundant, taking convenience, has the Chinese medicine of treatment type 2 diabetes mellitus of the effect of the blood glucose that reduces the type 2 diabetes mellitus patient, blood fat, blood viscosity.Two provide a kind of preparation method of Chinese medicine preparation of treatment type 2 diabetes mellitus of simple operation.
The object of the invention is achieved through the following technical solutions:
A kind of Chinese medicine preparation for the treatment of diabetes, this Chinese drugs agentia are to be made by the following raw medicaments in portion by weight thing: 5～60 parts of the Radixs Astragali, 3～20 parts of Radix Ginsengs, 5～20 parts of Radix Rehmanniae Preparata, 5～20 parts of Radix Ophiopogonis, 5～30 parts of Fructus Lycii, 1～10 part of Fructus Schisandrae Chinensis.
A kind of preparation method for the treatment of the Chinese medicine preparation of diabetes, this method is a water extraction, comprises the steps:
A. take by weighing raw materials of traditional Chinese medicinal materials according to weight portion; 5～60 parts of the Radixs Astragali, 5～20 parts of Radix Rehmanniae Preparata, 5～20 parts of Radix Ophiopogonis, 5～30 parts of Fructus Lycii, 1～10 part of Fructus Schisandrae Chinensis, decoct with water twice, by weight, the addition that at every turn decocts water is 8 times of five tastes medical material total weight parts, decocts 2 hours at every turn, filter, merging filtrate is concentrated into extractum
B. get 3～20 parts of Radix Ginsengs according to weight portion, be dried and be ground into 200 purpose fine powders, with the described extractum mixing of step a, drying is ground into fine powder as active component;
C. the described active component of step b is made various dosage forms with carrier or the excipient pharmaceutically accepted.
The inventor is in medical research, and from Chinese medical theory, through infrastest and in conjunction with clinical experience, think that the common pathogenesis of diabetes is: YIN fluid deficiency, scorching inclined to one side victory, the deficiency of YIN are this, and scorching for marking, disease has blood stasis (blood stasis) for a long time concurrently.According to the diabetics clinical manifestation be polydipsia, polyphagia, polyuria, become thin, symptom such as spiritlessness and weakness, founded the treatment rule of supplementing QI and nourishing YIN, promoting the production of body fluid to quench thirst, heat clearing and blood circulation promoting, prescription in addition under the guidance of this treatment rule.
The effect of each flavor Chinese crude drug of the present invention and the effect in prescription thereof are described below:
The Radix Astragali: this product is the dry root of leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao or Radix Astragali Astragalus membranaceus (Fisch.) Bge..Sweet, temperature is returned lung, spleen channel.Its main component is astragalus polysaccharides, flavone, saponin, betanin, trace element-selenium, chromium etc.; Invigorating QI to consolidate the body surface resistance is arranged, the effect of diuresis poison holding, it is weak to be used for the deficiency of vital energy, the exterior deficiency spontaneous perspiration, interior-heat is quenched one's thirst, diabetes.
Radix Ginseng: this product is the dry root and rhizome of Araliaceae Radix Ginseng Panax ginseng C.A.Mey..Sweet, little hardship, flat.Return spleen, lung, heart channel.Its main component is ginsenoside, polypeptide, polysaccharide, flavone etc.; Strongly invigorating primordial QI is arranged, and multiple arteries and veins takes off admittedly, and invigorating the spleen to benefit the lung promotes the production of body fluid, the effect of calming the nerves.Be used for weak body and prostration, Tianjin wound is thirsty, and interior-heat is quenched one's thirst, and prolonged illness is empty wins.
Radix Rehmanniae: this product is the fresh or dried root of scrophulariaceae rehmannia glutinosa plant Rehmannia glutinosa Libosch..Sweet, cold, GUIXIN, liver, kidney channel.Clearing away heat and cooling blood is arranged, YIN nourishing and the production of body fluid promoting, promoting blood circulation is by arthralgia due to stagnation of blood effects such as (Shennong's Herbals).Be used for interior-heat caused by deficiency of YIN, big hot excessive thirst, interior-heat is quenched one's thirst etc.Radix Rehmanniae Preparata: this product is the process of preparing Chinese medicine processed goods of Radix Rehmanniae.Sweet, tepor.Return liver, kidney channel.Its main component is Radix Rehmanniae oligosaccharide, polysaccharide, iridoid glycoside, Martynoside. A, catalpol, trace element chromium etc.; The effect that has nourishing YIN and supplementing blood, beneficial essence to fill out marrow.Be used for the hepatic and renal YIN deficiency, soreness of the waist and knees, interior-heat are quenched one's thirst etc.
Radix Ophiopogonis: this product is the dried root of liliaceous plant Ophiopogon Radix Ophiopogonis japonicus (Thunb.) Ker-Gawl..Sweet, little hardship is slightly cold, GUIXIN, lung, stomach warp.Radix Ophiopogonis, main component was Radix Ophiopogonis polysaccharide, saponin, steroidal class, trace element chromium etc.; YIN nourishing and the production of body fluid promoting is arranged, the effect that lung moistening clears away heart-fire.Be used for that Tianjin wound is thirsty, interior-heat is quenched one's thirst, vexed insomnia etc.
Fructus Lycii: this product is the dry mature fruit of plant of Solanaceae lycium barbarum Lycium barbarum L..Sweet, flat, return liver, kidney channel.The Fructus Lycii main component is lycium barbarum polysaccharide, betanin, trace element-selenium, chromium etc.; Nourishing the liver and kidney is arranged, the effect of replenishing vital essence to improve eyesight.Be used for the asthenia damage of essence, soreness of the waist and knees, dizzy ear toot, interior-heat is quenched one's thirst, blood deficiency and yellow complexion, blurred vision is not clear etc.
Fructus Schisandrae Chinensis: this product is the dry mature fruit of magnoliaceae schisandra Schisandra chinensis (Turcz.) Baill..Sour, sweet, temperature is returned lung, the heart, kidney channel.The Fructus Schisandrae Chinensis main component is lignanoid, polysaccharide etc.; The effect that astringent or styptic treatment for spontaneous sweating, the supplementing QI for promoting the production of body fluid of convergence, kidney calming are arranged.Be used for spontaneous perspiration, night sweat, Tianjin wound is thirsty, and interior-heat is quenched one's thirst, palpitation and insomnia etc.
Combinations thereof medicine of the present invention can be used as the prescription of Chinese traditional treatment diabetes (diabetes), frying in shallow oil soup for the type 2 diabetes mellitus patient takes, be more suitable for modern pharmaceutical enterprise effective component extracting, make any dosage form on the pharmaceuticss such as granule, capsule, tablet, oral liquid, because flavonoid glycoside is soluble in water, have very strong hypoglycemic activity, alkaloid is soluble in water to have remarkable hypoglycemic activity; Polysaccharide is soluble in water, has stronger hypoglycemic activity, and glycoside is generally water-soluble, and saponin is soluble in hot water, can promote insulin to discharge the blood sugar regulation metabolism; The general water soluble of polypeptide class.
Compared with the prior art, substantive distinguishing features and the significance progress given prominence to of the present invention is:
1, the present invention is under Chinese medical theory instructs, after the zoopery proof, and preferred above-mentioned Chinese medicine, in addition science compatibility, making cooperatively interact each medicine, learn from other's strong points to offset one's weaknesses, and synergism, all medicines share, and treating both the principal and secondary aspects of a disease heightens the effect of a treatment.
2, the present invention is raw materials used is integration of edible and medicinal herbs all, and toxicity is little, has overcome the particularly toxic and side effects of Western medicine of other hypoglycemic medicine, and behind the life-time service Western medicine to the shortcoming of the infringement of Liver and kidney.By using the daily dose and the course of treatment product of the present invention is safe.This product compares with metformin, and its blood sugar reducing function is suitable with the metformin effect, and comparing with Western medicine does not have toxic and side effects.
3, through zoopery and clinical verification product of the present invention type 2 diabetes mellitus patient fasting glucose and 2 hours after the meal blood glucose are reduced, and it is longer to hold time, person's cholesterol and triglyceride reduce also to make the hyperlipidemia simultaneously, and be evident in efficacy.
4, prescription science, raw material is easy to get, and generates the technology advanced person, and is simple and easy to do, workable, and moderate product price is fit to preparation of industrialization.
5, Radix Ginseng adopts superfine disintegrating process, and full powder is used as medicine, and has kept the effective ingredient of Radix Ginseng fully, has reached maximum and has utilized.
6, in the preparation process according to active ingredient, character and the preparation requirement of each Chinese medicine, adopt water extraction, physical sterilization method, thereby product active constituent content height, stable, not perishable, help long preservation.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
The present invention is a raw material with six medicines such as the Radix Astragali, Radix Ginsengs, by weight, weighs 5～60 parts of the Radixs Astragali, 3～20 parts of Radix Ginsengs, 5～20 parts of Radix Rehmanniae Preparata, 5～20 parts of Radix Ophiopogonis, 5～30 parts of Fructus Lycii, the Chinese drugs agentia of 1～10 part of preparation treatment of Fructus Schisandrae Chinensis type 2 diabetes mellitus.
Its preparation method adopts water extraction, and its method adopts two kinds of methods
First method comprises the following steps: to take by weighing raw materials of traditional Chinese medicinal materials according to above-mentioned consumption; The Radix Astragali, Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii, Fructus Schisandrae Chinensis are decocted with water twice, add 8 times of water gagings at every turn, decocted 2 hours at every turn, filter, merging filtrate is concentrated into extractum, again Radix Ginseng is dried and crushed into impalpable powder, with above-mentioned extractum mixing, drying is ground into fine powder as active component; Then above-mentioned active component is made various dosage forms with pharmaceutically acceptable carrier or excipient.
Second method comprises the following steps: to take by weighing raw materials of traditional Chinese medicinal materials according to above-mentioned consumption; Decoct with water twice, add 8 times of water gagings at every turn, decocted 2 hours at every turn, filter, merging filtrate is concentrated into extractum, as active component; Make various dosage forms with pharmaceutically acceptable carrier or excipient.
Specific embodiment:
Embodiment 1: the preparation of granule
Take by weighing according to following weight portion: 9 parts of the Radixs Astragali, 3 parts of Radix Ginsengs, 5 parts of Radix Rehmanniae Preparata, 5 parts of Radix Ophiopogonis, 5 parts of Fructus Lycii, 3 parts of Fructus Schisandrae Chinensis.
By weight, it is standby at first 3 parts of Radix Ginsengs to be ground into 200 order impalpable powders, 9 parts of the medicinal residues after it is pulverized and the Radixs Astragali, 5 parts of Radix Rehmanniae Preparata, 5 parts of Radix Ophiopogonis, 5 parts of Fructus Lycii, 3 parts of mixing and water addings of Fructus Schisandrae Chinensis decoct twice, and the addition of water is 8 times of five tastes medicine mixture weight part, the each decoction 2 hours, decoction liquor filters, and filtrate merges, and leaves standstill 12 hours, getting supernatant concentration to relative density is 1.20_1.30 (50-70 ℃), with above-mentioned 200 order impalpable powder mixings be extract powder, get extract powder: dextrin: starch: microcrystalline Cellulose=5: 1: 2: 2, mixing, granulate, drying is made granule, promptly gets name of product and is ginseng stilbene Qi granule.
Embodiment 2: the preparation of granule
Take by weighing 9 parts of the Radixs Astragali according to following weight portion, 3 parts of Radix Ginsengs, 5 parts of Radix Rehmanniae Preparata, 5 parts of Radix Ophiopogonis, 5 parts of Fructus Lycii, 3 parts of Fructus Schisandrae Chinensis.
Above-mentioned Chinese crude drug mixing and water adding is decocted twice, and the addition of water is 8 times of medicinal mixture weight portion, decocts 2 hours at every turn, and decoction liquor is filtered, and merging filtrate is concentrated into extractum, and drying is ground into 200 order fine powders; Add an amount of supplementary product starch, mixing makes name of product and is ginseng stilbene Qi granule.
Embodiment 3: the preparation of capsule
Take by weighing 20 parts of the Radixs Astragali according to following weight portion, 8 parts of Radix Ginsengs, 8 parts of Radix Rehmanniae Preparata, 7 parts of Radix Ophiopogonis, 10 parts of Fructus Lycii, 5 parts of Fructus Schisandrae Chinensis.
8 parts of Radix Ginsengs are ground into 200 order impalpable powders, standby, 20 parts of the medicinal residues after it is pulverized and the Radixs Astragali, 8 parts of Radix Rehmanniae Preparata, 7 parts of Radix Ophiopogonis, 10 parts of Fructus Lycii, 5 parts of mixing and water addings of Fructus Schisandrae Chinensis decoct twice, and the addition of water is 8 times of medicinal mixture weight portion, decocts 2 hours at every turn, filter, filtrate merges, and leaves standstill 12 hours, get supernatant concentration to an amount of, with 200 order Radix Ginseng impalpable powder mixings, drying, incapsulate, promptly get name of product and be ginseng stilbene wheat field capsule.
Embodiment 4: the preparation of capsule
Take by weighing 20 parts of the Radixs Astragali according to following weight portion, 8 parts of Radix Ginsengs, 8 parts of Radix Rehmanniae Preparata, 7 parts of Radix Ophiopogonis, 10 parts of Fructus Lycii, 5 parts of Fructus Schisandrae Chinensis.
Above-mentioned Chinese crude drug mixing and water adding is decocted twice, and the addition of water is 8 times of medicinal mixture weight portion, decocts 2 hours at every turn, filters, merging filtrate is concentrated into extractum, drying, be ground into 200 purpose fine powders, incapsulate, promptly get name of product and be ginseng stilbene Qi capsule.
Embodiment 5: the preparation of tablet
Take by weighing 60 kilograms of the Radixs Astragali according to weight meter (every weight portion is 1 kilogram), 20 kilograms of Radix Ginsengs, 20 kilograms of Radix Rehmanniae Preparata, 20 kilograms of Radix Ophiopogonis, 30 kilograms of Fructus Lycii, 1 kilogram of Fructus Schisandrae Chinensis.
20 kilograms of Radix Ginseng powder are broken into 200 purpose impalpable powders, standby, 60 kilograms of the remaining medicinal residues and the Radixs Astragali, 20 kilograms of Radix Rehmanniae Preparata, 20 kilograms of Radix Ophiopogonis, 30 kilograms of Fructus Lycii, 1 kilogram of mixing and water adding of Fructus Schisandrae Chinensis decocts twice, the weight that each decoction adds water is 8 times of medicinal mixture weight, promptly adds 1208 kilograms in water.The each decoction 2 hours filtered, and filtrate merges, and leaves standstill 12 hours, gets supernatant concentration to an amount of, with 200 purpose Radix Ginseng impalpable powder mixings, makes granule, drying, and compacting promptly gets name of product and is ginseng stilbene Qi sheet in flakes.
Embodiment 6: the preparation of tablet
Take by weighing 60 kilograms of the Radixs Astragali according to weight meter (every weight portion is 1 kilogram), 20 kilograms of Radix Ginsengs, 20 kilograms of Radix Rehmanniae Preparata, 20 kilograms of Radix Ophiopogonis, 30 kilograms of Fructus Lycii, 1 kilogram of Fructus Schisandrae Chinensis.
Above-mentioned Chinese crude drug mixing and water adding is decocted twice, and the weight that each decoction adds water is 8 times of medicinal mixture weight, promptly adds 1208 kilograms in water.The each decoction 2 hours filtered, merging filtrate, and evaporation and concentration is to extractum, and drying is ground into fine powder, and compacting promptly gets name of product and is ginseng stilbene Qi sheet in flakes.
Embodiment 7: the preparation of oral liquid
Take by weighing 30 kilograms of the Radixs Astragali according to weight meter (every weight portion is 1 kilogram), 10 kilograms of Radix Ginsengs, 10 kilograms of Radix Rehmanniae Preparata, 10 kilograms of Radix Ophiopogonis, 15 kilograms of Fructus Lycii, 5 kilograms of Fructus Schisandrae Chinensis.
Six medicaments mixing and water addings such as the Radix Astragali are decocted twice, add 8 times of water gagings at every turn, the weight that each decoction adds water is 8 times of medicinal mixture weight, promptly adds 640 kilograms in water.The each decoction 2 hours filtered, and merging filtrate left standstill 12 hours, gets supernatant concentration to an amount of, mixes with above-mentioned impalpable powder, adds flavoring agent again, antiseptic is an amount of, and mixing is made name of product for joining stilbene Qi oral liquid.
Embodiment 8: the preparation of pill
Take by weighing 10 kilograms of the Radixs Astragali according to weight meter (every weight portion is 1 kilogram), 7 kilograms of Radix Ginsengs, 8 kilograms of Radix Rehmanniae Preparata, 8 kilograms of Radix Ophiopogonis, 10 kilograms of Fructus Lycii, 2 kilograms of Fructus Schisandrae Chinensis.
With 10 kilograms of the Radixs Astragali, 8 kilograms of Radix Rehmanniae Preparata, 8 kilograms of Radix Ophiopogonis, 10 kilograms of Fructus Lycii, 2 kilograms of mixing and water addings of Fructus Schisandrae Chinensis decoct twice, and the weight that each decoction adds water is 8 times of medicinal mixture weight, promptly adds 304 kilograms in water.The each decoction 2 hours filtered, and merging filtrate is concentrated into extractum, again 7 kilograms of Radix Ginsengs is dried and crushed into 200 purpose impalpable powders, and with above-mentioned extractum mixing, drying is ground into fine powder; Add an amount of all adjuvants such as starch of going into, mixing, water is general to be ball, uses the Pulvis Fumi Carbonisatus coating, hits light, drying promptly gets name of product and is ginseng stilbene Qi ball.
Embodiment 9: the preparation of pill
Take by weighing 10 kilograms of the Radixs Astragali according to weight meter (every weight portion is 1 kilogram), 7 kilograms of Radix Ginsengs, 8 kilograms of Radix Rehmanniae Preparata, 8 kilograms of Radix Ophiopogonis, 10 kilograms of Fructus Lycii, 2 kilograms of Fructus Schisandrae Chinensis.
Above-mentioned Chinese crude drug is decocted with water twice, add 8 times of water gagings at every turn, the weight that each decoction adds water is 8 times of medicinal mixture weight, promptly adds 360 kilograms in water.The each decoction 2 hours filtered, and merging filtrate is concentrated into extractum, and drying is ground into fine powder; Add an amount of excipient, mixing, water is general to be ball, uses the Pulvis Fumi Carbonisatus coating, hits light, drying promptly gets name of product and is ginseng stilbene Qi ball.
Excipient in the preparation method of the present invention, the addition of adjuvant according to the concrete condition in the preparation process, are grasped flexibly, just " an amount of described in the literary composition.
Instructions of taking: granule, every day 3 times, each one bag, every bag 10 gram; Capsule, every day 3 times, each 3, every 0.35 gram; Tablet, every day 3 times, each 3～4, every 0.3 gram; Oral liquid, every day 3 times, each 10ml; Pill: every day 3 times, each 30, every 0.1 gram.Ante cibum or one after each meal.Attention: child or hypoglycemia person need not or careful usefulness.
The present invention is that Hygiene Toxicology teaching and research room acute toxicity testing proves through Huabei Coal Medical Sciences College's preventive medicine, and this product acute oral toxicity belongs to nontoxic substantially.
Pharmacological evaluation of the present invention is as follows:
Ginseng stilbene Qi granule is to the influence of type 2 diabetes mellitus rat blood sugar
(1) materials and methods
(1) trial drug SHENQI JIANGTANG KELI: provide by Lunan Pharmaceutical Co., Ltd..(authentication code: the accurate word Z10950075 of traditional Chinese medicines)
(2) animal wistar rat is purchased the Bioisystech Co., Ltd in Beijing Kang Lan of China Concord Medical Science University of Chinese Academy of Medical Sciences institute of lab animals, SPF level, the animal quality certification number: SCXK＜capital〉2009-0004, body weight 120 ± 20g.Be male.
(3) the reagent streptozotocin is provided by universal love businessman from Hongkong trade center, Beijing.
(4) method is got 70 wistar rats, is divided into 7 groups at random, i.e. blank group (saline), model group, western medicine group, Chinese medicine matched group, this medicine high dose group, middle dosage group, low dose group.Weigh weekly 1 time, and corresponding adjustment dosage, 4 weeks of logotype, the matched group list is given saline and is observed the activities in rats situation at any time, in 4 weeks of administration, measure the blood glucose of every group of rat etc. from the blood sampling of tail point, in putting to death administration group matched group all animals 4 weeks, and cut open and get main organs, send the pathological tissue chamber to check.
(2) result
(1) the administration group rat that influences of animal ordinary circumstance is compared the ordinary circumstance Non Apparent Abnormality with the blank group.
(2) the blood glucose check result medicine of the present invention there was no significant difference (P＞0.05) of comparing with metformin group, SHENQI JIANGTANG KELI group.
We are with the Radix Astragali, Radix Ginseng, Fructus Lycii compatibility supplementing QI and nourishing YIN, Radix Ophiopogonis, Fructus Schisandrae Chinensis compatibility promoting the production of body fluid to quench thirst, Radix Ophiopogonis, Radix Rehmanniae and the Radix Astragali mutually 5, heat clearing and blood circulation promoting dissipating blood stasis.Full side has the effect of supplementing QI and nourishing YIN, promoting the production of body fluid to quench thirst, heat clearing and blood circulation promoting.
More than disclosed only be specific embodiments of the invention; though the present invention discloses as above with preferred embodiment; but the present invention is not limited thereto; any those skilled in the art can think variation; in not breaking away from design philosophy of the present invention and scope; the present invention is carried out various changes and retouching, all should drop within protection scope of the present invention.
Claims (4)
1. a Chinese medicine preparation for the treatment of type 2 diabetes mellitus is characterized in that, this Chinese medicine preparation is to be made by the following raw medicaments in portion by weight thing: 5～60 parts of the Radixs Astragali, 3～20 parts of Radix Ginsengs, 5～20 parts of Radix Rehmanniae Preparata, 5～20 parts of Radix Ophiopogonis, 5～30 parts of Fructus Lycii, 1～10 part of Fructus Schisandrae Chinensis.
2. the Chinese medicine preparation of treatment type 2 diabetes mellitus according to claim 1 is characterized in that, described Chinese medicine preparation is made by the material medicine of following preferred weight part: 9 parts of the Radixs Astragali, 3 parts of Radix Ginsengs, 5 parts of Radix Rehmanniae Preparata, 5 parts of Radix Ophiopogonis, 5 parts of Fructus Lycii, 3 parts of Fructus Schisandrae Chinensis.
3. the preparation method of a treatment type 2 diabetes mellitus Chinese medicine preparation as claimed in claim 1 is characterized in that, this method is a water extraction, comprises the steps:
A. take by weighing raw materials of traditional Chinese medicinal materials according to weight portion, 5～60 parts of the Radixs Astragali, 5～20 parts of Radix Rehmanniae Preparata, 5～20 parts of Radix Ophiopogonis, 5～30 parts of Fructus Lycii, 1～10 part of Fructus Schisandrae Chinensis decocts with water twice, by weight, each addition that decocts water is 8 times of five tastes medical material total weight parts, decocts 2 hours at every turn, filters, merging filtrate is concentrated into extractum;
B. get 3～20 parts of Radix Ginsengs according to weight portion, be dried and be ground into 200 purpose fine powders, with the described extractum mixing of step a, drying is ground into fine powder as active component;
C. the described active component of step b is made various dosage forms with carrier or the excipient pharmaceutically accepted.
4. the preparation method of the Chinese medicine preparation of treatment type 2 diabetes mellitus according to claim 3, it is characterized in that, this method comprises the steps: to take by weighing 5～60 parts of the Radixs Astragali according to weight portion, 3～20 parts of Radix Ginsengs, 5～20 parts of Radix Rehmanniae Preparata, 5～20 parts of Radix Ophiopogonis, 5～30 parts of Fructus Lycii, 1～10 part of Fructus Schisandrae Chinensis, the six medicaments mixing and water adding is decocted twice, by weight, the addition that at every turn decocts water is 8 times of Six-element medical material total weight parts, decocts 2 hours at every turn, filter, merging filtrate is concentrated into extractum, as active component; This active component is directly made various dosage forms with carrier or the excipient pharmaceutically accepted.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102215616A CN101862413B (en) | 2010-07-09 | 2010-07-09 | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102215616A CN101862413B (en) | 2010-07-09 | 2010-07-09 | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101862413A true CN101862413A (en) | 2010-10-20 |
| CN101862413B CN101862413B (en) | 2012-01-18 |
Family
ID=42954471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102215616A Expired - Fee Related CN101862413B (en) | 2010-07-09 | 2010-07-09 | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101862413B (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771725A (en) * | 2015-03-17 | 2015-07-15 | 魏芹 | Deficiency cold type diabetes treatment medicine |
| CN106267039A (en) * | 2016-11-14 | 2017-01-04 | 华北理工大学 | Compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus and preparation method thereof |
| CN106267040A (en) * | 2016-11-14 | 2017-01-04 | 华北理工大学 | Compound Chinese medicinal preparation for the treatment of diabetes and preparation method thereof |
| CN106267038A (en) * | 2016-11-14 | 2017-01-04 | 华北理工大学 | A kind of compound Chinese medicinal preparation for the treatment of diabetes and preparation method thereof |
| CN106334160A (en) * | 2016-11-14 | 2017-01-18 | 华北理工大学 | Traditional Chinese medicine compound preparation for treating diabetes mellitus type 2 and complications and preparing method thereof |
| CN106362100A (en) * | 2016-11-14 | 2017-02-01 | 华北理工大学 | Traditional-Chinese-medicine compound preparation for treating damaged function of islet of 2-type diabetes mellitus and preparation method thereof |
| CN106390034A (en) * | 2016-11-14 | 2017-02-15 | 华北理工大学 | Traditional Chinese medicine compound preparation for curing 2-diabetes |
| CN108114148A (en) * | 2018-02-08 | 2018-06-05 | 江西林丰药业有限公司 | A kind of Chinese medicine composition for treating diabetes and preparation method thereof |
| CN109717426A (en) * | 2018-12-24 | 2019-05-07 | 江苏辰星药业股份有限公司 | A kind of hypoglycemia healthcare food and preparation method thereof |
| CN110613792A (en) * | 2019-09-19 | 2019-12-27 | 中南大学湘雅二医院 | Traditional Chinese medicine composition with blood sugar reducing effect and preparation method and application thereof |
| CN113318192A (en) * | 2021-05-12 | 2021-08-31 | 王杰 | Umbilical dropping liquid for diabetic patients and preparation method thereof |
| CN113797303A (en) * | 2020-06-17 | 2021-12-17 | 北京圣手苗医堂企业管理有限公司 | A Chinese medicinal composition for treating diabetes, and its preparation method |
| WO2022021780A1 (en) * | 2020-07-28 | 2022-02-03 | 深圳市老年医学研究所 | Medicated diet and dietary therapy composition for type 2 diabetes and preparation method therefor |
| CN116139216A (en) * | 2022-11-09 | 2023-05-23 | 陕西含光生物科技有限公司 | Compound traditional Chinese medicine and extract thereof and application of compound traditional Chinese medicine in treatment of glycolipid metabolic diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616014A (en) * | 2004-09-17 | 2005-05-18 | 鲁南制药股份有限公司 | Chinese medicine composition for treating diabetes and its preparing method |
| CN101138369A (en) * | 2006-09-06 | 2008-03-12 | 蔡如桂 | Thirst-eliminating tea |
| CN101468141A (en) * | 2007-12-24 | 2009-07-01 | 李勇 | Medicine for treating diabetes |
-
2010
- 2010-07-09 CN CN2010102215616A patent/CN101862413B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616014A (en) * | 2004-09-17 | 2005-05-18 | 鲁南制药股份有限公司 | Chinese medicine composition for treating diabetes and its preparing method |
| CN101138369A (en) * | 2006-09-06 | 2008-03-12 | 蔡如桂 | Thirst-eliminating tea |
| CN101468141A (en) * | 2007-12-24 | 2009-07-01 | 李勇 | Medicine for treating diabetes |
Non-Patent Citations (2)
| Title |
|---|
| 《天津药学》 20021031 刘曦婷 糖尿病的中药治疗 第11-13页 1-4 第14卷, 第5期 2 * |
| 《首都医药》 20070430 程京艳等 糖尿病的中医分型及临床常用中成药 第45-46页 1-4 , 2 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104771725A (en) * | 2015-03-17 | 2015-07-15 | 魏芹 | Deficiency cold type diabetes treatment medicine |
| CN104771725B (en) * | 2015-03-17 | 2018-09-18 | 魏芹 | A kind of drug for treating cold of insufficiency type patients with type Ⅰ DM |
| CN106334160A (en) * | 2016-11-14 | 2017-01-18 | 华北理工大学 | Traditional Chinese medicine compound preparation for treating diabetes mellitus type 2 and complications and preparing method thereof |
| CN106267038A (en) * | 2016-11-14 | 2017-01-04 | 华北理工大学 | A kind of compound Chinese medicinal preparation for the treatment of diabetes and preparation method thereof |
| CN106267040A (en) * | 2016-11-14 | 2017-01-04 | 华北理工大学 | Compound Chinese medicinal preparation for the treatment of diabetes and preparation method thereof |
| CN106362100A (en) * | 2016-11-14 | 2017-02-01 | 华北理工大学 | Traditional-Chinese-medicine compound preparation for treating damaged function of islet of 2-type diabetes mellitus and preparation method thereof |
| CN106390034A (en) * | 2016-11-14 | 2017-02-15 | 华北理工大学 | Traditional Chinese medicine compound preparation for curing 2-diabetes |
| CN106267039A (en) * | 2016-11-14 | 2017-01-04 | 华北理工大学 | Compound Chinese medicinal preparation for the treatment of type 2 diabetes mellitus and preparation method thereof |
| CN108114148A (en) * | 2018-02-08 | 2018-06-05 | 江西林丰药业有限公司 | A kind of Chinese medicine composition for treating diabetes and preparation method thereof |
| CN109717426A (en) * | 2018-12-24 | 2019-05-07 | 江苏辰星药业股份有限公司 | A kind of hypoglycemia healthcare food and preparation method thereof |
| CN110613792A (en) * | 2019-09-19 | 2019-12-27 | 中南大学湘雅二医院 | Traditional Chinese medicine composition with blood sugar reducing effect and preparation method and application thereof |
| CN110613792B (en) * | 2019-09-19 | 2021-12-24 | 中南大学湘雅二医院 | Traditional Chinese medicine composition with blood sugar reducing effect and preparation method and application thereof |
| CN113797303A (en) * | 2020-06-17 | 2021-12-17 | 北京圣手苗医堂企业管理有限公司 | A Chinese medicinal composition for treating diabetes, and its preparation method |
| WO2022021780A1 (en) * | 2020-07-28 | 2022-02-03 | 深圳市老年医学研究所 | Medicated diet and dietary therapy composition for type 2 diabetes and preparation method therefor |
| CN113318192A (en) * | 2021-05-12 | 2021-08-31 | 王杰 | Umbilical dropping liquid for diabetic patients and preparation method thereof |
| CN116139216A (en) * | 2022-11-09 | 2023-05-23 | 陕西含光生物科技有限公司 | Compound traditional Chinese medicine and extract thereof and application of compound traditional Chinese medicine in treatment of glycolipid metabolic diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101862413B (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101862413B (en) | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof | |
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN104288501A (en) | Blood glucose reducing particle and preparation method thereof | |
| CN100475232C (en) | Oral medicine for treating diabetes and use thereof | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN102302673B (en) | Traditional Chinese medicine compound preparation for preventing and treating diabetic nephropathy (DN) | |
| CN101869663B (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN105918946A (en) | Red date and Chinese wolfberry fruit liver tonifying composition, granules and preparation method thereof | |
| CN101406598B (en) | Chinese medicine composite for treating diabetes and preparation method thereof | |
| CN101347605B (en) | Chinese medicinal composition for treating gout and preparation method and application thereof | |
| CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN101085121A (en) | Traditional Chinese medicine composition with hypoglycemic and antilipemic function and making method and application | |
| CN102526484B (en) | Medicinal composition for decreasing blood sugar | |
| CN103736052B (en) | Chinese medicine composition of a kind of auxiliary hyperglycemic and preparation method thereof | |
| CN103263658A (en) | Traditional Chinese medicine preparation for treating peripheral facial paralysis and preparation method thereof | |
| CN103385931A (en) | Blood-sugar-lowering medicine composition | |
| CN102755519B (en) | Kudzuvine root-kudzuvine flower anti-canker sore particle and preparation method thereof | |
| CN102233089B (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| WO2015018123A1 (en) | Traditional chinese medicine preparation for reducing blood sugar and preparation method thereof | |
| CN103948736B (en) | The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof | |
| CN115252729B (en) | Traditional Chinese medicine composition for treating diabetes and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HEBEI UNITED UNIVERSITY Free format text: FORMER OWNER: LA XIAOJIN Effective date: 20110719 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 063000 DEPARTMENT OF TRADITIONAL CHINESE MEDICINE, NORTH CHINA COAL MEDICALCOLLEGE, RESIDENTIAL QUARTER 57, JIANSHE SOUTH ROAD, LUBEI DISTRICT, TANGSHAN CITY, HEBEI PROVINCE TO: 063000 NO. 46, XINHUA WEST ROAD, TANGSHAN CITY, HEBEI PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110719 Address after: 063000 Hebei province Tangshan City Xinhua West Road No. 46 Applicant after: Hebei United University Address before: 063000 Hebei District, Tangshan City Road, North District, No. 57 South District, North China Coal Medical University, Department of traditional Chinese Medicine Applicant before: La Xiaojin |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120118 Termination date: 20120709 |